Elite Pharmaceuticals Stock Plunges Post Q1 Earnings, Revenues Fall Y/Y

Shares of Elite Pharmaceuticals, Inc. ELTP have lost 15.7% since the company reported earnings for the quarter ended June 30, 2026, underperforming the S&P 500 Index’s 0.6% decline over the same period. The stock has also plunged 21.2% over the past month, while the S&P 500 gained 2.9%.

Elite Pharmaceuticals’ Earnings Snapshot

For the first quarter of fiscal 2027, revenues declined 19.5% year over year to $32.4 million from $40.2 million. Net income was $5.9 million against a year-ago net loss of $5.9 million, while basic and diluted earnings per share improved to $0.01 from a loss of $0.01 per share. Operating income fell 65.3% to $7.5 million from $21.7 million.

Elite Pharmaceuticals operates as a single reportable segment, but its revenue mix showed divergent trends. Direct wholesaler sales decreased 13.8% to $16.4 million, while indirect wholesaler sales fell 24.2% to $15.7 million. Total ANDA revenues were $32.1 million, down 19.2% from $39.8 million, while licensing fees fell to $0.2 million from $0.4 million year over year.

Scheduled-product manufacturing fees declined 28.5% to $27.8 million, whereas unscheduled-product manufacturing fees increased to $4.3 million from $0.9 million year over year.

ELTP’s Other Key Business Metrics

Gross profit declined 50.4% year over year to $13.5 million, with gross margin contracting to 42% from 68%. Cost of manufacturing increased 45.1% to $18.8 million from $12.9 million, reflecting higher product volumes. Operating expenses rose 8.2% to $5.9 million, including a 21.3% increase in research and development (R&D) expenses to $2 million and a 4.3% rise in general and administrative expenses to $3.5 million. The higher R&D spending reflected costs associated with a successful pivotal bioequivalence study and an ANDA filing during the quarter.

Operating cash flow was $10.1 million compared with $14.8 million a year earlier. Cash stood at $38.9 million as of June 30, 2026, up from $29.8 million as of March 31, 2026. Management said that liquidity would primarily support new products, product-line expansion and facility improvements intended to accommodate additional products and higher production volumes.

Factors Influencing Elite Pharmaceuticals’ Results

Management attributed the revenue decline primarily to increased generic-market competition and lower average net selling prices, particularly for lisdexamfetamine, Elite Pharmaceuticals’ generic Vyvanse product. The year-ago quarter benefited from higher pricing shortly after the product entered the generic market. Management said that the market subsequently moved toward a steadier pricing environment, while volumes continued to trend higher. Cost of manufacturing also increased as product volumes rose, particularly for lisdexamfetamine and the Amphetamine IR and ER lines.

CEO Nasrat Hakim said that overall volume increased 14.75% from the year-ago quarter, including a 10% increase for lisdexamfetamine. Hakim added that market share increased across ELTP’s major lisdexamfetamine, Amphetamine IR, Amphetamine ER and Naltrexone products.

ELTP’s Outlook

Elite Pharmaceuticals did not provide formal financial guidance. Management nevertheless pointed to pipeline development as the primary avenue for future growth. Methadone was launched in April, while Ropinirole ER was launched in July.

ELTP also reported positive pivotal bioequivalence results for an undisclosed anticonvulsant product and filed an ANDA for an undisclosed anticoagulant in June. Generic OxyContin ER remains under FDA review, with management noting that an unresolved anti-abuse testing issue must be addressed before a potential August 2027 launch.

Elite Pharmaceuticals’ Other Developments

Elite Pharmaceuticals continues to evaluate strategic alternatives involving a potential buyout as well as a Nasdaq uplisting. Management said that the company remains open to an acquisition, being acquired or proceeding independently, but expects to pursue Nasdaq regardless. Hakim indicated that, based on the current timetable, an uplisting could be completed or nearing completion around February 2027.

ELTP is also considering manufacturing expansion that management said would require roughly two years to prepare and qualify additional space and equipment for future products.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research